# Crescendo Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crescendo-biologics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.crescendobiologics.com
- Total disclosed funding: $95M
- Latest round: Series B (Apr 30, 2018)
- Investors on record: 11

## About

Crescendo Biologics Limited, based in the UK, focuses on developing T cell-enhancing therapeutics with innovative solutions aimed at tackling unmet medical needs within immuno-oncology.Founded in 2007 and headquartered in Cambridge, UK, Crescendo Biologics Limited specializes in biopharmaceutical development. The firm has successfully completed 8 deals, with its most recent funding round in July 2023, raising USD 32.00 mn from investors including Kreos Capital and BioNTech SE. The company is led by CEO Theodora Harold, who has a history of involvement in the biotechnology sector.Crescendo Biologics specializes in the development of innovative T cell-enhancing therapeutics aimed at addressing unmet medical needs in the field of immuno-oncology. Their core product offerings include the Humabody® platform, which features a range of bispecific and multivalent antibodies designed to engage T cells and target specific tumor cells effectively. Notable products in development include CB307, a bispecific T cell engager currently in clinical trials for patients with metastatic castration-resistant prostate cancer (mCRPC), and ZL-1102 (Humabody®, CB001), a topical treatment for psoriasis being evaluated in a global Phase 2 clinical trial. The company's innovations are primarily targeted towards healthcare providers and pharmaceutical companies in North America, Europe, and Asia-Pacific regions, where they aim to provide advanced treatment options for patients suffering from various cancers and autoimmune diseases.Crescendo Biologics generated revenue of USD 8,032,513.30 in 2023, with an EBITDA of USD -27,185,349. The company generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions, enabling the development and commercialization of its proprietary products. Transactions typically involve licensing agreements and milestone payments contingent upon the successful progression of clinical trials for their flagship products, including Humabody® and Multibody® therapeutics. These agreements allow Crescendo Biologics to monetize its technologies while leveraging the expertise and resources of established partners to bring treatments to market. The revenue model is structured around research collaborations, development milestones, and potential royalties on future sales, enhancing the financial stability and growth prospects of the company as it continues to advance its innovative portfolio.In July 2023, Crescendo Biologics Limited raised USD 32.00 mn in venture funding to support the expansion of its adaptive clinical protocol. The funding will be utilized to advance the development of upcoming products, including new indications for the Humabody® platform. The company is targeting expansion into additional markets across Europe and Asia-Pacific by the end of 2024, aiming to broaden access to its therapeutics while enhancing its clinical trial capabilities.

## Funding rounds

- Series B, Apr 30, 2018, $68M — Sofinnova Partners, Andera Partners, EMBL Ventures, Longview Innovation, Takeda Ventures, Quan Capital
- Series A, Feb 19, 2014, $1.6M — EMBL Ventures
- Series A, Dec 6, 2013, $18M — Sofinnova Partners, Astellas Venture Management, Touchstone Innovations
- Seed, Dec 3, 2008, $6.9M — Avlar BioVentures, Sofinnova Partners, Future Planet Capital Regional, Aitua Ltd.

## Investors

- Avlar BioVentures (https://capitalatlas.ai/funds/avlar-bioventures) — Seed
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A, Series B
- Future Planet Capital Regional (https://capitalatlas.ai/funds/future-planet-capital-regional) — Seed
- Aitua Ltd. — Seed
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Series A
- EMBL Ventures (https://capitalatlas.ai/funds/embl-ventures) — Series A, Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series B